These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2112405)
21. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. Bartels GL; Remme WJ; Look MP; Kruijssen DA J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641 [TBL] [Abstract][Full Text] [Related]
22. Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects. Ng HW; Walley TJ; Tsao Y; Breckenridge AM Eur J Clin Pharmacol; 1994; 46(4):361-5. PubMed ID: 7957523 [TBL] [Abstract][Full Text] [Related]
23. A comparison of the effects of captopril and flosequinan in patients with severe heart failure. Cowley AJ; Wynne RD; Swami A; Birkhead J; Skene A; Hampton JR Cardiovasc Drugs Ther; 1992 Oct; 6(5):465-70. PubMed ID: 1450090 [TBL] [Abstract][Full Text] [Related]
24. Central and regional hemodynamic effects of flosequinan for congestive heart failure. Haas GJ; Binkley PF; Carpenter JA; Leier CV Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526 [TBL] [Abstract][Full Text] [Related]
25. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers. Lewis HM; Kendall MJ; Smith SR; Bratty JR Br J Clin Pharmacol; 1989 May; 27(5):547-52. PubMed ID: 2757879 [TBL] [Abstract][Full Text] [Related]
26. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers. Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945 [TBL] [Abstract][Full Text] [Related]
27. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. Packer M; Pitt B; Rouleau JL; Swedberg K; DeMets DL; Fisher L JACC Heart Fail; 2017 Jun; 5(6):399-407. PubMed ID: 28501522 [TBL] [Abstract][Full Text] [Related]
28. Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure. Perreault CL; Hague NL; Loh E; Hunneyball IM; Sim MF; Morgan JP Br J Pharmacol; 1992 Jul; 106(3):511-6. PubMed ID: 1324072 [TBL] [Abstract][Full Text] [Related]
29. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cowley AJ; McEntegart DJ; Hampton JR; Barnett DB; Bexton RS; Boyle R; Hanley SP; Millar-Craig M; Morris GK; Nicholls AJ Cardiovasc Drugs Ther; 1994 Dec; 8(6):829-36. PubMed ID: 7742261 [TBL] [Abstract][Full Text] [Related]
30. Effects of high-intensity interval training on central haemodynamics and skeletal muscle oxygenation during exercise in patients with chronic heart failure. Spee RF; Niemeijer VM; Wijn PF; Doevendans PA; Kemps HM Eur J Prev Cardiol; 2016 Dec; 23(18):1943-1952. PubMed ID: 27440661 [TBL] [Abstract][Full Text] [Related]
31. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. Binkley PF; Nunziata E; Cody RJ Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595 [TBL] [Abstract][Full Text] [Related]
32. Acute increase in exercise capacity with milrinone: lack of correlation with resting hemodynamic responses. Ribeiro JP; White HD; Hartley LH; Colucci WS Braz J Med Biol Res; 1990; 23(11):1069-78. PubMed ID: 2133014 [TBL] [Abstract][Full Text] [Related]
33. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Weber KT; Kinasewitz GT; Janicki JS; Fishman AP Circulation; 1982 Jun; 65(6):1213-23. PubMed ID: 6804111 [TBL] [Abstract][Full Text] [Related]
35. [Effects of aerobic training in patients with moderate chronic heart failure]. Belardinelli R; Scocco V; Mazzanti M; Purcaro A G Ital Cardiol; 1992 Aug; 22(8):919-30. PubMed ID: 1478392 [TBL] [Abstract][Full Text] [Related]
36. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. Hambrecht R; Niebauer J; Fiehn E; Kälberer B; Offner B; Hauer K; Riede U; Schlierf G; Kübler W; Schuler G J Am Coll Cardiol; 1995 May; 25(6):1239-49. PubMed ID: 7722116 [TBL] [Abstract][Full Text] [Related]
37. Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials. Cowley AJ; McEntegart DJ Int J Cardiol; 1993 Feb; 38(2):167-75. PubMed ID: 8454379 [TBL] [Abstract][Full Text] [Related]
38. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. Fazio S; Palmieri EA; Affuso F; Cittadini A; Castellano G; Russo T; Ruvolo A; Napoli R; Saccà L J Clin Endocrinol Metab; 2007 Nov; 92(11):4218-23. PubMed ID: 17698902 [TBL] [Abstract][Full Text] [Related]